SCHEMBL3773643

SCHEMBL3773643

O=C(C=Cc1ccccc1C(F)(F)F)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 1/20 0.48
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 3/20 0.48
NFKB1 P19838 1/20 0.45
PARP1 P09874 1/20 0.44
KEAP1 Q14145 2/20 0.43
NFE2L2 Q16236 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
F2R P25116 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
BACE1 P56817 1/20 0.40
P4HB P07237 1/20 0.40
MAOB P27338 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
WNT3 P56703 1/20 0.40
SFRP1 Q8N474 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773640 1.00 GPR183 (0.48) GPR183KDM4EALDH1A1NFKB1PARP1
SCHEMBL3803380 0.87 C3AR1 (0.47) GPR183KDM4EALDH1A1PARP1KEAP1
SCHEMBL3803381 0.87 C3AR1 (0.47) GPR183KDM4EALDH1A1PARP1KEAP1
SCHEMBL3769364 0.85 L3MBTL1 (0.60) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3769370 0.85 L3MBTL1 (0.60) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3763096 0.85 APP (0.47) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3763100 0.85 APP (0.47) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3767564 0.83 PARP1 (0.43) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3767573 0.83 PARP1 (0.43) GPR183KDM4EALDH1A1PARP1F2R
SCHEMBL3767551 0.83 KDM4E (0.54) KDM4EALDH1A1PARP1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 GPR183 59/4885KDM4E 534/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.